Literature DB >> 1455985

Screening for unruptured familial intracranial aneurysms. A decision analysis.

D W Dippel1, J W ter Berg, J D Habbema.   

Abstract

Decision analysis is used to assess the decision to screen for unruptured intracranial aneurysms (IAs) in two affected families, and to formulate guide-lines for similar decisions. Four strategies are compared: "no screening", "screening directly", "screening twice", and "screening later". Intravenous and intra-arterial digital subtraction angiography techniques (iv-DSA, ia-DSA) are considered. Life years lived with and without disability are computed for each strategy. Loss of life expectancy with and without discounting and quality correction is used as an outcome measure. "No screening" is the preferred strategy when population based estimates of the prevalence of IAs are used. Thus, the results of this analysis provide no justification for screening patients without a familial history. But a physician who thinks that the risk of an IA is increased may rightly decide for screening, especially when the patient is aged 40 to 60. Ia-DSA is preferable over iv-DSA. A scenario analysis suggests that screening with magnetic resonance angiography is only slightly better than with ia-DSA, because the complication rate of screening plays a minor role in the analysis.

Entities:  

Mesh:

Year:  1992        PMID: 1455985     DOI: 10.1111/j.1600-0404.1992.tb05105.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Acoustic detection of intracranial aneurysms: a decision analysis.

Authors:  A C van Bruggen; D W Dippel; J D Habbema; J J Mooij
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Unruptured intracranial arteriovenous malformations with hereditary haemorrhagic telangiectasia. Neurosurgical treatment or not?

Authors:  J W ter Berg; D W Dippel; J D Habbema; C J Westermann; C A Tulleken; J Willemse
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.